| Formulary Chapter 6: Endocrine system - Full Chapter
|
| 06.02.02 |
Antithyroid drugs |
|
|
Methylthioninium chloride injection 0.5%, 1%, 2% (methylene blue)
|
 Unlicensed
|
 Diagnostic agent used for staining parathyroid glands.
Maximal staining of glands occurs if infused intravenously for 1 hour prior to operation
Dose: 5 mg/kg actual body weight in 250 mL dextrose/saline
|
Methylthioninium chloride injection 2% (methylene blue)
|
Unlicensed
|
 For testing intragastric balloon insertions and as a dye for patients with polyps undergoing colonoscopies (Endoscopy/Day Surgery)
For checking bladder patency secondary to injury during C-sections and checking fallopian tube patency (Birth Centre Theatres)
|
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Specialist or hospital prescribing only.
The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital.
In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.
|
|
Treatment can be initiated in primary care after a recommendation from an appropriate specialist |
|
Specialist initiation followed by maintenance prescribing in primary care |
|
Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation |
|
Specialist and non-specialist initiation |
|
Not recommended for prescribing |
|
|
